Trinity Biotech Plc Stock Buy Hold or Sell Recommendation
| TRIB Stock | USD 1.10 0.02 1.79% |
Given the investment horizon of 90 days and your conservative attitude towards risk, our recommendation regarding Trinity Biotech plc is 'Strong Sell'. Macroaxis provides Trinity Biotech buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding TRIB positions.
Check out Trinity Biotech Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Trinity and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Trinity Biotech plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Trinity |
Execute Trinity Biotech Buy or Sell Advice
The Trinity recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Trinity Biotech plc. Macroaxis does not own or have any residual interests in Trinity Biotech plc or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Trinity Biotech's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Moves totally opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Trinity Biotech Trading Alerts and Improvement Suggestions
| Trinity Biotech plc generated a negative expected return over the last 90 days | |
| Trinity Biotech plc has high historical volatility and very poor performance | |
| Trinity Biotech plc may become a speculative penny stock | |
| Trinity Biotech plc has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 56.83 M. Net Loss for the year was (24.02 M) with profit before overhead, payroll, taxes, and interest of 38.08 M. | |
| Trinity Biotech plc currently holds about 10.01 M in cash with (11.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41. | |
| Roughly 20.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from bizjournals.com: 800-acre, mixed-use development targeted for Trinity is in the early stages |
Trinity Biotech Returns Distribution Density
The distribution of Trinity Biotech's historical returns is an attempt to chart the uncertainty of Trinity Biotech's future price movements. The chart of the probability distribution of Trinity Biotech daily returns describes the distribution of returns around its average expected value. We use Trinity Biotech plc price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Trinity Biotech returns is essential to provide solid investment advice for Trinity Biotech.
| Mean Return | -0.84 | Value At Risk | -8.29 | Potential Upside | 13.33 | Standard Deviation | 6.15 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Trinity Biotech historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Trinity Stock Institutional Investors
| Shares | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 2.7 K | Sjs Investment Consulting Inc. | 2024-09-30 | 2 K | Rhumbline Advisers | 2024-09-30 | 1.8 K | Jones Financial Companies Lllp | 2024-06-30 | 308 | Bank Of America Corp | 2024-06-30 | 240 | Atlantic Trust Group, Llc | 2024-06-30 | 222 | Simplex Trading, Llc | 2024-06-30 | 42.0 | Atwood & Palmer Inc | 2024-09-30 | 20.0 | Stonehill Capital Management Llc | 2024-06-30 | 0.0 | Perceptive Advisors Llc | 2024-09-30 | 1.8 M | Hunter Associates Inc. | 2024-09-30 | 359.8 K |
Trinity Biotech Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (3.0M) | (3.4M) | (4.4M) | (877K) | (971K) | (1.0M) | |
| Change In Cash | (13.9M) | 10.9M | (1.4M) | (19.3M) | (2.9M) | (2.7M) | |
| Free Cash Flow | (9.9M) | 13.6M | 4.5M | (6.9M) | (14.3M) | (13.5M) | |
| Depreciation | 4.9M | 3.1M | 2.7M | 2.3M | 1.8M | 1.7M | |
| Other Non Cash Items | (10.6M) | 22.3M | 8.9M | 37.9M | 11.4M | 11.9M | |
| Capital Expenditures | 15.4M | 10.2M | 8.7M | 6.0M | 803K | 762.9K | |
| Net Income | 12.2M | (6.4M) | 875K | (41.0M) | (24.0M) | (22.8M) | |
| End Period Cash Flow | 16.4M | 27.3M | 25.9M | 6.6M | 3.7M | 3.5M | |
| Net Borrowings | (11.9M) | (3.5M) | 1.3M | (1.1M) | (969.3K) | (920.8K) | |
| Change To Netincome | 31.0M | 30.4M | 27.4M | 12.8M | 14.7M | 14.0M | |
| Investments | (11.9M) | (10.2M) | (8.7M) | (6.0M) | 24.8M | 26.0M |
Trinity Biotech Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Trinity Biotech or Health Care Equipment & Supplies sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Trinity Biotech's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Trinity stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.86 | |
β | Beta against Dow Jones | 0.08 | |
σ | Overall volatility | 6.08 | |
Ir | Information ratio | -0.16 |
Trinity Biotech Volatility Alert
Trinity Biotech plc is displaying above-average volatility over the selected time horizon. Trinity Biotech plc is a potential penny stock. Although Trinity Biotech may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Trinity Biotech plc. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Trinity instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Trinity Biotech Fundamentals Vs Peers
Comparing Trinity Biotech's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Trinity Biotech's direct or indirect competition across all of the common fundamentals between Trinity Biotech and the related equities. This way, we can detect undervalued stocks with similar characteristics as Trinity Biotech or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Trinity Biotech's fundamental indicators could also be used in its relative valuation, which is a method of valuing Trinity Biotech by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Trinity Biotech to competition |
| Fundamentals | Trinity Biotech | Peer Average |
| Return On Equity | -19.13 | -0.31 |
| Return On Asset | -0.0964 | -0.14 |
| Profit Margin | (0.38) % | (1.27) % |
| Operating Margin | (0.11) % | (5.51) % |
| Current Valuation | 120.92 M | 16.62 B |
| Shares Outstanding | 27.32 M | 571.82 M |
| Shares Owned By Insiders | 19.68 % | 10.09 % |
| Shares Owned By Institutions | 23.90 % | 39.21 % |
| Number Of Shares Shorted | 76.94 K | 4.71 M |
| Price To Earning | 31.00 X | 28.72 X |
| Price To Book | 5.11 X | 9.51 X |
| Price To Sales | 0.52 X | 11.42 X |
| Revenue | 56.83 M | 9.43 B |
| Gross Profit | 38.08 M | 27.38 B |
| EBITDA | (24.1 M) | 3.9 B |
| Net Income | (24.02 M) | 570.98 M |
| Cash And Equivalents | 10.01 M | 2.7 B |
| Cash Per Share | 0.41 X | 5.01 X |
| Total Debt | 67.43 M | 5.32 B |
| Current Ratio | 3.66 X | 2.16 X |
| Book Value Per Share | (3.12) X | 1.93 K |
| Cash Flow From Operations | (11.56 M) | 971.22 M |
| Short Ratio | 0.43 X | 4.00 X |
| Earnings Per Share | (2.25) X | 3.12 X |
| Price To Earnings To Growth | 1.30 X | 4.89 X |
| Target Price | 3.0 | |
| Number Of Employees | 380 | 18.84 K |
| Beta | 1.13 | -0.15 |
| Market Capitalization | 30.46 M | 19.03 B |
| Total Asset | 59.44 M | 29.47 B |
| Retained Earnings | (48.64 M) | 9.33 B |
| Working Capital | 24.01 M | 1.48 B |
| Current Asset | 151 M | 9.34 B |
Trinity Biotech Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Trinity . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Trinity Biotech Buy or Sell Advice
When is the right time to buy or sell Trinity Biotech plc? Buying financial instruments such as Trinity Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Trinity Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Restaurants Thematic Idea Now
Restaurants
Entities that are involved in restaurant business, as well as coffee shop chains and other eateries. The Restaurants theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Restaurants Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trinity Biotech Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Biotech. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trinity Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (2.25) | Revenue Per Share 6.968 | Quarterly Revenue Growth 0.14 | Return On Assets (0.1) |
The market value of Trinity Biotech plc is measured differently than its book value, which is the value of Trinity that is recorded on the company's balance sheet. Investors also form their own opinion of Trinity Biotech's value that differs from its market value or its book value, called intrinsic value, which is Trinity Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trinity Biotech's market value can be influenced by many factors that don't directly affect Trinity Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trinity Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Trinity Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.